Carcinogenicity
All insulin analogs must be tested for carcinogenicity, as insulin engages in cross-talk with IGF pathways, which can cause abnormal cell growth and tumorigenesis. Modifications to insulin always carry the risk of unintentionally enhancing IGF signalling in addition to the desired pharmacological properties.. Recently there has been concern with the carcinogenicity of glargine but is yet to be proven. The FDA has instructed for a large scale study evaluating the carcinogenicity of glargine. The study result is expected in a few years.
Read more about this topic: Insulin Analog